Elekta (STO:EKTA B) shares are down today after the Swedish medtech maker reported lower profits for its fiscal 2014 1st half.

Stockholm-based Elekta posted profits of kr183 million ($28.1 million), or kr0.48 (7¢) per share, on sales of kr4.36 billion ($668.3 million) for the 6 months ended Oct. 31. That’s a profit slide of 33.0% on sales growth of 4.2%.

"It is gratifying to see that our long-term growth strategy is continuing to be successful. Elekta’s order bookings increased 10% [on a constant-currency basis] in the 2nd quarter. In Europe, the Middle East and Africa order bookings was particularly strong and increased by 32% [on a constant-currency basis]. In North America, order bookings rose 21% [on a constant-currency basis], which was significantly higher than the market as a whole. In Asia Pacific we remain confident of the performance for the full year. In the quarter order bookings declined, but this should be viewed in light of the sharp increase noted in the preceding year," president & CEO Tomas Puusepp said in prepared remarks.

Elekta reiterated its full-year outlook, saying it still expects to post sales growth of more than 10% on a constant-currency basis.

EKTA B shares were trading at kr91.80 ($14.09) apiece as of about 10 a.m. Eastern today, down 4.8%.